As a Théa’s dedicated business unit, Sepul Bio is at the forefront of transformative RNA therapies for inherited retinal diseases, with a particular focus on the development of two cutting-edge ophthalmic solutions – Sepofarsen and Ultevursen. Sepofarsen targets Leber congenital amaurosis 10 (LCAACL10), a rare genetic disease causing severe visual impairment, while Ultevursen is designed to halt vision loss in people with a mutation in exon 13 of the USH2A gene and suffering from retinitis pigmentosa. Our mission, within the framework of Théa’s established expertise, is to pionneer breakthroughs in the treatment of inherited retinal diseases, offering hope to people facing these challenging conditions. Through collaboration, specialized know-how and unwavering dedication, Sepul Bio is committed to accelerating innovation in ophthalmic solutions and improving the lives of those affected by rare genetic eye diseases, most specifically through the development of these two groundbreaking products.
